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Amphetamines induce tissue factor and impair tissue factor
pathway inhibitor: role of dopamine receptor type 4
Abstract
Aims Amphetamine intake is associated with acute vascular syndromes. Since these events are caused
by arterial thrombosis and this in turn is triggered by tissue factor (TF), this study examines whether
amphetamines regulate TF in human endothelial cells. Methods and results Amphetamine (10(-7)-10(-4)
mol/L) enhanced thrombin- and tumour necrosis factor (TNF)-alpha-induced as well as basal TF
expression (P = 0.029, 0.0003, and 0.003 at maximal concentration), and TNF-alpha-induced
plasminogen activator inhibitor (PAI)-1 expression (P = 0.003), whereas tissue factor pathway inhibitor
expression was impaired (P = 0.008). Similarly, 3,4-methylenedioxymethamphetamine (10(-7)-10(-4)
mol/L) enhanced TF expression (P = 0.046). These effects were paralleled by an increased TF activity
(P = 0.002); moreover, clotting time of human plasma was accelerated by supernatant from
amphetamine-treated cells (P = 0.03). Amphetamine enhanced TF mRNA expression via
phosphorylation of the mitogen-activated protein kinases (MAPKs) extracellular signal-regulated kinase
(ERK) and p38 (P = 0.03 and 0.033), but not c-Jun NH(2)-terminal kinase (JNK; P = 0.81). The effect
of amphetamine on TF expression was abrogated by the dopamine D4 receptor antagonists L-745,870
and L-750,667, but not D2 or D3 receptor antagonists; furthermore, L-745,870 blunted the
amphetamine-induced activation of ERK and p38, but not JNK. Conclusion Amphetamines induce
endothelial TF expression via stimulation of dopamine D4 receptor and activation of the MAPKs p38
and ERK. These effects occur at clinically relevant amphetamine concentrations and may account for
the increased incidence of acute vascular syndromes after amphetamine consumption.
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Abstract 
 
Aims: Amphetamine intake is associated with acute vascular syndromes. Since 
these events are caused by arterial thrombosis and this in turn is triggered by tissue 
factor (TF), this study examines whether amphetamines regulate TF in human 
endothelial cells. 
Methods and Results: Amphetamine (10-7-10-4 mol/L) enhanced thrombin and TNF-
α induced as well as basal TF expression (p=0.029, p=0.0003, and p=0.003 at 
maximal concentration), and TNF-α induced PAI-1 expression (p=0.003), while tissue 
factor pathway inhibitor (TFPI) expression was impaired (p=0.008). Similarly, 
methylenedioxy-methamphetamine (MDMA, 10-7-10-4 mol/L) enhanced TF 
expression (0.046). These effects were paralleled by an increased TF activity 
(p=0.002), moreover, clotting time of human plasma was accelerated by supernatant 
from amphetamine treated cells (p=0.03). Amphetamine enhanced TF mRNA 
expression via phosphorylation of the MAP kinases ERK and p38 (p=0.03 and 
p=0.033), but not JNK (p=0.81). The effect of amphetamine on TF expression was 
abrogated by the dopamine D4 receptor antagonists L-745,870 and L-750,667, but 
not D2 or D3 receptor antagonists; furthermore, L-745,870 blunted the amphetamine 
induced activation of ERK and p38, but not JNK. 
Conclusions: Amphetamines induce endothelial TF expression via stimulation of 
dopamine D4 receptor and activation of the MAP kinases p38 and ERK. These 
effects occur at clinically relevant amphetamine concentrations and may account for 
the increased incidence of acute vascular syndromes after amphetamine 
consumption.  
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Introduction 
 
In the Western civilization, intake of psychostimulants such as amphetamine 
and methylenedioxymethamphetamine (MDMA, “Ecstasy”) has risen dramatically 
over the past decade; as a consequence, this phenomenon has now turned into a 
major public burden (1). The problem is aggravated by the fact that the majority of 
consumers are young (≤ 45 years) and thus often faced with unexpected acute 
cardiovascular events (2). Indeed, numerous publications report amphetamine-
associated acute vascular syndromes including myocardial infarction and ischemic 
stroke (3-8).  
The pathogenesis of amphetamine-related acute cardiovascular events is still 
uncertain. Vasospasm and prothrombotic state have been postulated as etiologic 
factors, but no solid evidence is available to support these assumptions (3, 4, 9). The 
combination of vasospasm and thrombosis does indeed seem to play a role in 
coronary artery occlusion, indicating a dynamic interaction of vasoconstriction and 
thrombus formation in acute vascular syndromes (10). Further, substances 
suspected to promote vasospasm, such as histamine and cocaine, are known to 
induce the endothelial expression of tissue factor (TF) (11, 12). TF is the main trigger 
of coagulation and crucially involved in arterial thrombus formation, the central event 
in acute vascular syndromes (13). In this context, it is important to note that 
amphetamines are known to activate MAP kinases, the major regulators of 
endothelial TF expression, in neuronal cells (14). Based on these facts, we 
hypothetized that amphetamine may induce TF expression. Hence, this study was 
designed to examine the effect of amphetamines on TF expression in human 
vascular endothelial cells. 
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 Materials and Methods 
 
Cell culture 
 Human aortic endothelial cells (HAECs; Clonetics, Allschwil, Switzerland) were 
cultured as described (15). Cells were grown to confluence and were then serum 
withdrawn for 24 hrs by using EBM medium (Cambrex) supplemented with 0.5% 
FCS, before stimulation with 5 ng/mL TNF-α (R&D, Minneapolis, MN) or 1 U/mL 
thrombin (Sigma-Aldrich, Buchs, Switzerland) (Table 1). Cells were pretreated with 
amphetamine (Lipomed, Arlesheim, Switzerland) or 3,4-
methylenedioxymethamphetamine (MDMA; Sigma-Aldrich) for 60 min before 
stimulation with TNF-α. Dopamine, L-750,667, L-745,870, raclopride (all from Sigma-
Aldrich), NGB 2904 (Tocris Bioscience, Ellisville, MOi) were added to the dishes 60 
min before stimulation (Table 1). Cytotoxicity was assessed with a colorimetric assay 
to detect lactate dehydrogenase release (Roche, Basel, Switzerland). The use of 
MDMA in this study was approved by the Swiss Health Authority (reference: AB-8/5-
BetmG-07.001315).  
 
Western blot  
Protein expression was determined by Western blot analysis as described(16). 
Antibodies against human TF and tissue factor pathway inhibitor (TFPI; both from 
American Diagnostica, Stamford, CT) were used at 1:2000 dilution. Antibody against 
plasminogen activator inhibitor (PAI-1; Santa Cruz) was applied at 1:4000 dilution.  
Antibodies against phosphorylated p38 MAP kinase (p38), p44/42 MAP kinase 
(extracellular signal–regulated kinase [ERK]), and c-Jun NH2-terminal kinase (JNK; 
all from Cell Signaling, Danvers, MA) were used at 1:1000, 1:5000, and 1:1000 
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dilution, respectively. Antibodies against total p38, ERK, and JNK (all from Cell 
Signaling) were used at 1:3000, 1:2000, and 1:1000 dilution, respectively. Antibodies 
against Thr-34 and Thr-75 phosphorylated as well as against total dopamine-and-
cAMP-regulated Phosphoprotein 32 (DARPP-32) (Cell Signaling, Danvers, MA) were 
used at 1:1000 dilution. Anti-goat glyceraldehyde-3-phosphate dehydrogenase 
antibody (GAPDH; Chemicon, Temecula, CA) was applied to ensure equal protein 
loading (1:20000 dilution). Proteins were detected with a horseradish peroxidase–
linked secondary antibody (Amersham, Munich, Germany). 
 
Real-time PCR 
Total RNA was extracted from HAEC using TRIzol Reagent (Invitrogen). 
Conversion of total cellular RNA to cDNA was carried out with Moloney murine 
leukaemia virus reverse transcriptase and random hexamers (Amersham Bioscience) 
in a final volume of 33 μL using 4 μg of cDNA. All real-time PCR experiments were 
performed in triplicate using the SYBR Green JumpStart kit (Sigma) in an MX3000P 
PCR cycler (Stratagene, Amsterdam, The Netherlands). Each reaction (25 μL) 
contained 2 μL cDNA, 10 pmol of each primer, 0.25 μL of internal reference dye, and 
12.5 μL of JumpStart Taq ReadyMix (containing buffer, dNTPs, stabilizers, SYBR 
Green, Taq polymerase, and JumpStart Taq antibody). The following primers were 
used: for tissue factor: sense 5’-TCCCCAGAGTTCACACCTTACC-3’ (bases 508-529 
of F3 cDNA; NCBI no. NM 001993), antisense: 5’-CCTTTCTCCTGGCCCATACAC-3’ 
(bases 843-863 of TF cDNA; NCBI no. NM 001993); for human D4 dopamine 
receptor: sense: 5’-CCCACCCCAGACTCCACC-3’ (bases 963-980 of DRD4 cDNA; 
NCBI no. NM 000797), antisense: 5’-GAACTCGGCGTTGAAGACAG-3’ (bases 1202-
1221 of DRD4 cDNA; NCBI no. 000797); for human L28: sense: 5’-
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GCATCTGCAATGGATGGT-3’, antisense: 5’-CCTTTCTCCTGGCCCATACAC-3’. 
The amplification program consisted of 1 cycle at 95˚C for 10 min, followed by 35 
cycles with a denaturing phase at 95˚C for 30 s, an annealing phase at 60°C for 1 
min and an elongation phase at 72˚C for 1 min. A melting curve analysis was 
performed after amplification to verify the accuracy of the amplicon. PCR products 
were also analyzed on an ethidium bromide stained 1.5% agarose gel. In each real-
time PCR run, a calibration curve was included that was generated from serial 
dilutions of the respective purified amplicons. TF mRNA stability was assessed in the 
presence of the transcriptional inhibitor actinomycin D (10 ug/mL, Sigma-Aldrich, 
Buchs, Switzerland), which was added 2 hrs after TNF-α stimulation. Cells were 
harvested for RNA extraction at various time-points (0–3 hrs) following actinomycin D 
treatment. The copy numbers for TF obtained in the real-time PCR analysis were 
normalized to those of L28, and the values are presented as percent of the TNF-α 
alone group. 
 
Gene silencing through siRNA transfection 
Three siRNA sequences specific for the human dopamine receptor 4 (D4) were 
applied for knocking down D4 expression using the N-TER™ Nanoparticle siRNA 
Transfection System (Sigma, Saint Louis, USA). These siRNA sequences were as 
follows: siRNA 1 (sense: 5’-CCGCCUCCAUCUUCAACCUdTdT-3’; antisense: 5’-
AGGUUGAAGAUGGAGGCGGdTdT-3’); siRNA 2 (sense: 5’-
CCCUCAUGGCCAUGGACGUdTdT-3’; antisense: 5’-
ACGUCCAUGGCCAUGAGGGdTdT-3’); siRNA 3 (sense: 5’-
GCCUCCAUCUUCAACCUGUdTdT-3’; antisense: 5’-
ACAGGUUGAAGAUGGAGGCdTdT-3’). Briefly, cells were transfected with a 15 nM 
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siRNA Nanoparticle Forming Solution (NFS) and incubated with transfection serum-
free medium for the following 4 h at 37°C. Subsequently, cells were cultured in the 
serum-containing growth medium for 24-48 h at 37°C. 
 
TF activity 
 TF activity was analyzed at the luminal surface of adherent endothelial cells 
and in whole cell lysates of HAEC using a colorimetric assay (American Diagnostica). 
TF/FVIIa converted factor X to factor Xa, which was measured by its ability to 
metabolize a chromogenic substrate. A standard curve with lipidated human TF was 
performed to assure that measurements were taken in the linear range of detection. 
 
Clotting time 
 Clotting time was assessed using a Start fibrometer. 50 μL of supernatant 
from HAECs were harvested and incubated with 50 μL of citrated human plasma for 
1 min. Coagulation was initiated by the addition of 25 mM calcium chloride followed 
by analysis of clotting time.  
 
Statistics 
 Differences between mean data were compared by the non parametric Mann-
Whitney-test and Jonckheere-Terpstra test, respectively, for non-Gaussian variables, 
however, due to the low number of experiments, those tests must not refer to the 
usual normal approximation. In case of a significant global test (> 2 groups), the 
Dunn’s multiple comparison test was used for pairwise group comparison. All 
statistical decisions were made two-tailed with a 95% confidence interval. Data are 
reported as mean ± SEM. All tests used exact probability distributions. A two-tailed P-
 9 
value of 0.05 was chosen as cut-off for statistical significance at hypothesis testing. 
Statistical analyses were performed using GraphPad Prism software, version 4.03 
(GraphPad Software Inc., La Jolla, CA, USA) and SPSS for Windows, version 17.0 
(SPSS Inc, Chicago, IL, USA).  
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Results 
 
Amphetamines enhance TF protein expression and activity 
HAECs were stimulated with TNF-α (5 ng/ml) or thrombin (1 U/mL) for 5 hours 
in the presence or absence of amphetamines (Table 1). Amphetamine (10-7-10-4 
mol/L) enhanced TNF-α induced TF expression in a concentration-dependent 
manner reaching a 1.8-fold induction (n=7; p=0.0003; Mann Whitney test; Figure 1A, 
Table 2). Similarly, amphetamine enhanced thrombin induced TF expression by 1.6-
fold (n=4; p=0.029; Mann Whitney test; Figure 1C; Table 2) and basal TF expression 
by 2.2-fold (n=7; p=0.003; Mann Whitney test; Figure 1D; Table 2). Similar to 
amphetamine, MDMA (10-7-10-4 mol/L) enhanced TF expression by 1.7-fold at 
maximum concentration as compared to TNF-α alone (n=4; p=0.046; Mann Whitney 
test; Figure 1B; Table 2). The effect of amphetamine and MDMA on TF protein 
expression was paralleled by an increased TF surface activity both in TNF-α 
stimulated cells (n=5-6; p=0.002 and p=0.008, respectively; Mann Whitney test; 
Figure 2A and 2B; Table 2) and under basal conditions (n=6; p=0.002; Mann Whitney 
test; Figure 2D; Table 2). Amphetamine induced a similar relative increase in TF 
surface activity and TF whole cell activity (n=5; p=0.004; Mann Whitney test; Figure 
2C; Table 2). 
 
Amphetamines are not toxic 
To control for toxic effects, HAECs were treated with increasing 
concentrations of amphetamine or MDMA for 6 hours. Morphological examination did 
not reveal any changes (n=9; data not shown); moreover, no signs of toxicity were 
detected by LDH release for any concentration of amphetamine or MDMA used (n=9; 
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data not shown).  
 
Amphetamine accelerates clotting time of human plasma  
To assess the functional relevance of amphetamine induced TF expression, 
the effect of supernatant from amphetamine treated HAECs on clotting time of 
human plasma was assessed. Clotting time was accelerated by supernatant from 
cells treated with amphetamine both under basal conditions (n=6; p=0.03; Mann 
Whitney test; Supplemental Figure 1; Table 2) and after stimulation with TNF-α (n=6; 
p=0.002; Mann Whitney test; Supplemental Figure 1; Table 2). 
 
Amphetamine impairs TFPI and increases PAI-1 expression  
Increasing concentrations of amphetamine (10-7-10-4 mol/L) inhibited 
expression of TFPI in TNF-α and thrombin stimulated HAECs resulting in a 45% and 
36% reduction, respectively (n=4-5; p=0.008 and p=0.03, respectively; Mann Whitney 
test; Figure 3B and 3C; Table 2). A similar effect was observed under basal 
conditions (n=4; p=0.03; Mann Whitney test; Figure 3A; Table 2). In contrast, 
amphetamine (10-4 mol/L) increased endothelial PAI-1 expression following TNF-α 
stimulation (n=6; p=0.003; Mann Whitney test; Table 2). 
 
Amphetamine enhances TF mRNA expression without affecting mRNA stability 
Real-time PCR demonstrated that TF mRNA expression was induced after 2 
hours of TNF-α stimulation (n=4; p=0.029; Mann Whitney test; Figure 4A). Treatment 
with amphetamine enhanced TNF-α induced TF mRNA expression in a 
concentration-dependent manner reaching a maximal induction of 2.1-fold (n=4; 
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p=0.032; Mann Whitney test; Figure 4A; Table 2). Amphetamine did not affect the 
stability of TF mRNA under these conditions (n=4; Figure 4B).  
 
Amphetamine enhances MAP kinase activation 
To assess whether amphetamine alters MAP kinase activation, HAECs were 
examined at different time points after cytokine stimulation. The MAP kinases p38, 
ERK, and JNK were transiently activated by TNF-α (n=4; Figure 6A). Amphetamine 
enhanced phosphorylation of p38 and ERK (n=4-7; p=0.033 and p=0.03, 
respectively; Mann Whitney test; Figure 5A and B; Table 2), while that of JNK 
remained unaffected (n=4; p=0.81; Mann Whitney test; Figure 5A and B). No 
significant change in total expression of MAP kinases was observed at any time point 
with or without amphetamine. The MAP kinase inhibitors SB203580, PD98059, and 
SP600125, which specifically act on p38, ERK, and JNK, respectively, impaired TF 
expression after TNF-α stimulation (n=4; p<0.05 for TNF-α alone versus each 
inhibitor; Mann Whitney test; Figure 5C). Phosphorylation of dopamine-and-cAMP-
regulated Phosphoprotein 32 (DARPP-32) was not altered in the presence or 
absence of amphetamine (data not shown). MAPK inhibitors were not toxic as 
assessed by LDH-release measured 5 hours after addition of TNF-α (n=3; data not 
shown). 
 
Dopamine D4 receptor mediates the effect of amphetamine on TF  
Some of the psychotropic effects of amphetamine are known to be mediated 
by dopamine receptors. Endothelial cells express dopamine D2, D3, and D4 
receptors, and these receptors are known to modulate endothelial activation. 
Expression of the dopamine D4 receptor in HAECs was confirmed by PCR (n=5; data 
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not shown). Dopamine indeed enhanced TNF-α induced TF expression in HAECs 
(n=6; p=0.002; Mann Whitney test; Figure 6A; Table 2). To determine whether 
dopamine receptors are involved in amphetamine induced TF expression, cells were 
pretreated with amphetamine, the D2 receptor antagonist raclopride, the D3 receptor 
antagonist NGB 2904, or the D4 receptor antagonists L-745,870 and L-750,667. 
Pretreatment with L-745,870 abrogated amphetamine induced TF expression (n=5; 
p=0.02; Jonckheere-Terpstra test; Figure 6B; Table 2), and a similar effect was 
observed with L-750,667 (n=3; p=0.03; Jonckheere-Terpstra test; data not shown). In 
contrast, the effect of amphetamine remained unaltered by pretreatment with 
raclopride or NGB 2904 (n=4; p=1.0 and 0.46, respectively; Jonckheere-Terpstra 
test; Figure 6C and D; Table 2). When the D4 receptor gene was silenced through 
siRNA transfection, the effect of amphetamine on TF expression was abrogated, 
whereas non targeting siRNA had no effect on amphetamine induced TF expression 
(n=6; p=0.03 for amphetamine in non targeting siRNA transfected cells versus 
amphetamine in D4R siRNA transfected cells; Mann Whitney test; Figure 6E). 
Blocking the dopamine D4 receptor with L-745,870 (10-5 mol/L) abrogated the 
amphetamine induced phosphorylation of p38 (n=4; p=0.03 for amphetamine and L-
745,870 versus amphetamine alone; Mann Whitney test; Figure 7A)  and ERK (n=4; 
p=0.03 for amphetamine and L-745,870 versus amphetamine alone; Mann Whitney 
test; Figure 7B), while activation of JNK remained unaffected (n=4; p=0.34 for 
amphetamine and L-745,870 versus amphetamine alone; Mann Whitney test; Figure 
7C). L-745,870 alone did not affect the TNF-α induced activation of MAP kinases 
(n=4; Figure 7). Total expression of MAP kinases remained unchanged at all time 
under all conditions (n=4; data not shown). Lactate dehydrogenase release did not 
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reveal any cytotoxic effect of dopamine, raclopride, NGB 2904, L-745,870, or L-
750,667 (n=3; data not shown).  
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Discussion 
 
Amphetamine consumption can lead to death due to cardiovascular events 
and is becoming an increasingly serious worldwide concern. Indeed, data from more 
than 30 case reports and 8 epidemiologic studies support this tendency. 
Amphetamine associated adverse cardiovascular events mostly occur in relatively 
young individuals with no previous history of cardiovascular disease. Consistent with 
this observation, myocardial ischemia with angiographically normal coronary arteries 
is documented in amphetamine consumers (2, 17). A recent report described severe 
anterior myocardial infarction with pump failure due to proximal thrombotic occlusion 
of the LAD in a 28 year old amphetamine consumer (18). Similar reports have 
demonstrated intravascular thrombosis, either angiographically or in postmortem 
examination, in such patients (18, 19). In the present study, amphetamines are 
shown to induce TF expression and surface activity in human endothelial cells; this 
effect occurred at the transcriptional level and was mediated through the dopamine 
D4 receptor leading to activation of the MAP kinases p38 and ERK. Since TF is the 
key trigger of thrombosis, our observations offer a potential mechanism for the 
occurrence of acute vascular syndromes in amphetamine consumers. 
The concentrations applied in the present study are within the plasma range 
observed in vivo; indeed, a plasma concentration of 5 x 10-6 mol/L (1.1 μg/ml) was 
measured 6 hours following MDMA intake in a subject who developed massive 
thrombosis of the right coronary artery (19). However, there is a large variability of 
amphetamine plasma levels in patients presenting to the emergency department, and 
up to 100-fold higher plasma concentrations in the range of 0.4 - 84.0 μg/ml for 
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MDMA and  0.2 - 11.3 μg/ml (8 x 10-5 mol/L) for amphetamine were measured in 
amphetamine victims (20).  
In contrast to cocaine, amphetamine induced TF expression and activity in 
both quiescent and cytokine-stimulated endothelial cells (12, 21-23). Considering that 
the endothelium plays a pivotal role in modulating the hemostatic balance, this 
observation adds on to the evidence that amphetamine may trigger thrombus 
formation in the absence of inflammatory alterations, as it may occur in young 
amphetamine consumers. Furthermore, amphetamine enhanced TF expression in 
response to TNF-α, an inflammatory cytokine known to induce TF expression in 
endothelial cells (13). Hence, amphetamines may upregulate TF expression in an 
inflammatory environment as it is observed in patients exposed to cardiovascular risk 
factors, but without clinically manifest atherosclerosis. Inflammation is indeed an 
important trigger for the pathogenesis of arterial thrombosis (24), and inflammatory 
markers such as C-reactive protein are significantly raised in patients suffering from 
myocardial infarction at a young age (25). In addition, the enhancing effect of 
amphetamine on thrombin induced TF expression suggests that amphetamine may 
not only induce, but also amplify thrombus formation converting a small and clinically 
non-significant thrombus into an occlusive thrombosis leading to an acute vascular 
syndrome.  
TF activity is counterbalanced by TFPI, and the equilibrium of these two 
factors is indeed essential in determining thrombus formation (11), (13). Besides its 
effects on TF, amphetamine reduced endothelial TFPI, both in quiescent and TNF-
alpha or thrombin stimulated cells, indicating that the effect of amphetamine on TFPI 
does not depend on the activation status of the cells. Moreover, in parallel to 
enhancing TF and decreasing TFPI, amphetamine increased TNF-alpha induced 
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PAI-1 expression. PAI-1 is a serpin suppressing fibrinolysis by inhibiting the activity 
of tissue plasminogen activator (tPA). Therefore, amphetamine would indeed be 
expected to exert potent prothrombotic actions in vivo by modulating different 
mediators of haemostasis.  
 The functional relevance of the enhanced TF activity in amphetamine treated 
HAECs was underlined by the observation that supernatant from amphetamine 
treated cells accelerated clotting time of human plasma; this effect occurred with cells 
treated with amphetamine under both basal conditions and after cytokine stimulation. 
These data, although performed in vitro, add on to the evidence that amphetamine 
may trigger thrombus formation in amphetamine consumers by enhancing 
coagulation.   
Dopamine receptors play a role in mediating the behavioral effects of 
amphetamine (26-28). Earlier studies have convincingly shown that blockade of 
dopamine D4 receptor in rats prevents the acute stimulatory effects of amphetamine 
(29) and dopamine receptor blockade in mice attenuates amphetamine induced 
hyperlocomotion (28). While many studies have investigated amphetamine mediated 
signalling in the brain, no efforts have been made in identifying amphetamine 
induced events in peripheral cells. Dopamine receptors are expressed in endothelial 
cells, can activate them, and mediate effects on coagulation factors (30-32). TF 
induction by amphetamine was indeed abrogated by dopamine D4 receptor 
antagonists or by silencing the D4 receptor gene through siRNA transfection. In line 
with this observation, expression of this receptor in human endothelial cells was 
confirmed; furthermore, its activation by dopamine was able to induce endothelial TF 
expression. Considering the very similar chemical structure of amphetamine and 
dopamine, it is possible that amphetamine directly activates endothelial dopamine 
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receptors; alternatively, amphetamine may increase locally synthesized extracellular 
dopamine by blocking dopamine transporters, as previously decribed in neuronal 
cells (33, 34). Most of the dopamine is indeed produced in non-neuronal locations 
such as renal tubules and endothelial cells of various organs (35-37); the latter being 
underlined by the identification of L-Dopa decarboxylase by RT-PCR in cultured 
endothelial cells (32).  
TF expression in response to a variety of stimuli is mediated by MAP kinase 
activation leading to increased TF transcription (13). Amphetamine indeed enhanced 
activation of p38 and ERK, but not JNK, resulting in enhanced TF mRNA expression; 
TF mRNA stability remained unaltered under these conditions. Inhibition of p38 and 
ERK impaired TF expression in response to TNF-α, confirming that the effect of 
amphetamine on p38 and ERK phosphorylation mediates the increase in TF 
expression. This signal transduction profile of amphetamine is consistent with recent 
observations demonstrating that p38 and ERK, but not JNK, are required for 
mediating amphetamine induced forms of reward-related learning in the prefrontal 
cortex (14). Blocking of the dopamine D4 receptor abolished activation of p38 and 
ERK, but not JNK, suggesting that amphetamine leads to activation of p38 and ERK 
via the dopamine D4 receptor. In line with this interpretation, stimulation of the 
dopamine D4 receptor produced a time- and dose-dependent increase in ERK 
activity in several brain regions (38, 39). Not surprisingly, MAP kinases, in particular 
the ERK pathway, have been described as a key molecular process in selective brain 
regions in response to amphetamine, and pharmacological manipulation of the ERK 
pathway has been proposed as a potential treatment strategy for drug addiction (40). 
 The present in vitro study has several limitations. We have not studied all the 
mechanism potentially influencing dopamine receptor signalling. Thus, further studies 
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are needed to understand the molecular mechanism by which dopamine receptor 
signalling is involved in the regulation of haemostasis and vascular biology. 
Moreover, animal and clinical studies need to clarify whether an increased TF activity 
indeed accounts for the effects of amphetamines on thrombus formation in vivo. 
In summary, this study demonstrates that amphetamine leads to an increase 
in endothelial TF expression and activity with a parallel decrease in TFPI expression. 
This effect is mediated by the dopamine D4 receptor and activation of the MAP 
kinases p38 and ERK. These findings may offer a mechanistic insight regarding 
amphetamine-induced acute cardiovascular events.  
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Figure legends 
 
Figure 1: Amphetamines enhance endothelial TF protein expression  
A. Amphetamine enhances TNF-α induced TF protein expression. *p<0.05 vs 
TNF-α alone. B. MDMA enhances TNF-α induced TF protein expression. *p<0.05 vs 
TNF-α alone C. Amphetamine enhances thrombin induced TF protein expression. 
*p<0.05 vs TNF-α alone D. Amphetamine induces basal TF protein expression. 
*p<0.05 vs unstimulated control. All blots are normalized to GAPDH expression. 
 
Figure 2: Amphetamine induces TF activity 
A. Amphetamine enhances TNF-α induced TF surface activity. *p<0.05 vs 
TNF-α alone B. MDMA enhances TNF-α induced TF surface activity. *p<0.05 vs 
TNF-α alone C. Amphetamine induces a similar relative increase in luminal surface 
activity and whole cell activity of TF. p<0.05 vs control D. Amphetamine induces 
basal TF surface activity. *p<0.05 vs unstimulated control 
 
Figure 3: Amphetamine inhibits endothelial TFPI protein expression 
A.  Amphetamine inhibits basal TFPI protein expression. *p<0.05 vs 
unstimulated control B. Amphetamine inhibits TFPI protein expression in TNF-α 
stimulated cells. *p<0.05 vs TNF-α alone C. Amphetamine inhibits TFPI protein 
expression in thrombin stimulated cells. *p<0.05 vs thrombin alone  
 
Figure 4: Amphetamine enhances endothelial TF mRNA expression without 
affecting mRNA stability 
 A. Amphetamine enhances TNF-α induced TF mRNA expression. *p<0.05 vs 
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TNF-α alone. Values are determined by real-time PCR, indicated as percent of TNF-
α alone, and normalized to L28 expression. B.  Amphetamine (10-4 M) does not affect 
TF mRNA stability. TF mRNA copies are normalized to L28 expression and 
expressed as percent of TNF-α. 
 
Figure 5: Amphetamine enhances endothelial TF expression via MAP kinase 
activation 
 A. Phosphoralytion pattern of MAP kinases p38, ERK, and JNK following 
amphetamine treatment in TNF-α atimulated cells. B. MAP kinase activation after 15 
min of amphetamine treatment, expressed as increase over TNF-α alone. *p<0.05 vs 
TNF-α alone C. The MAP kinase inhibitors PD98059, SB203580, and SP600125, 
specifically inhibiting ERK, p38, and JNK, respectively, impair TF expression after 
TNF-α stimulation. *p<0.05 for TNF-α alone vs each inhibitor 
 
Figure 6: Amphetamine enhances endothelial TF expression via dopamine D4 
receptor  
A. Dopamine enhances TNF-α induced endothelial TF expression. *p<0.05 vs. 
TNF-α alone B. The dopamine D4 receptor antagonist L-745,870 abrogates 
amphetamine-induced TF expression. *p<0.05 vs amphetamine alone C. The effect 
of amphetamine remains unaltered by the D2 receptor antagonist raclopride. D. The 
effect of amphetamine remains unaltered by the D3 receptor antagonist NGB 2904. 
E. Amphetamine enhanced TF expression is abrogated when D4 receptor gene is 
silenced through siRNA transfection. *p<0.05 vs versus amphetamine in D4R siRNA 
transfected cells. 
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Figure 7: Amphetamine activates p38 and ERK via dopamine D4 receptor 
Blocking of the dopamine D4 receptor with L-745,870 abolishes amphetamine 
induced activation of p38 and ERK, while JNK phosphorylation remains unaffected. 
*p<0.05 vs amphetamine alone. 
 
Supplemental Figure 1: Amphetamine accelerates clotting time of human 
plasma 
Clotting time of human plasma in the presence of supernatant from 
amphetamine treated HAECs under basal conditions and in the presence of TNF-α. 
*p<0.05 vs unstimulated and TNF-α alone, respectively.  
 
Table 1: Study conduct of the in vitro experiments.  
 
Table 2: Group comparison by Mann Whitney test.  Data are presented as 
mean±SEM  (% versus control group). ** Jonckheere-Terpstra test for multiple group 
comparison was applied. In case of a significant global test Dunn’s multiple 
comparison test was used for pairwise group comparison. DRA: dopamine receptor 
antagonist 
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CA, USA).
Study aim: to investigate whether amphetamine regulates TF in endothelial cells
Null hypothesis: no difference between the two groups tested
Experimental hypothesis: Amphetamines enhance endothelial TF expression
 
 
 
 
 
 
 
 
 
 
 
 
TF protein expression
- TNF-α stimulation (amphetamine)
- TNF-α stimulation (MDMA)
- Thrombin stimulation
- basal
- TNF-α stimulation (Dopamine)
- Dopamine 2R antagonist
- Dopamine 3R antagonist
- Dopamine 4R antagonist
TFPI expression
- TNF-alpha stimulation
- Thrombin stimulation
- basal
PAI-1 expression (TNF-α)
MAPK phosphorylation
- phoERK
- phop38
- phoJNK
TF surface activity
- TNF-α stimulation (amphetamine)
- TNF-α stimulation (MDMA)
- basal
Whole cell TF activity (TNF-α)
Clotting time
- basal
- TNF-α stimulation
TF mRNA expression
D4R siRNA transfection
Parameter Amphetamine 10-4M 
Mean ± SEM
n p value of 
Mann Whitney/Jonckheere-
Terpstra
181.1 ± 9.0
160.1 ± 23.7
216.7 ± 34.6
174.0 ± 18.6
174.0 ± 18.6
174.0 ± 18.6
56.5 ± 9.3
74.6 ± 9.6
61.5 ± 4.7
207.2 ± 24.7
159.6 ± 9.1
110.7 ± 16.4
102.1 ± 14.02
159.3 ± 9.1
168.0 ± 20.9
147.1 ± 10.3
79.5 ± 5.3
85.6 ± 2.8
203.6 ± 22.3
180.4 ± 15.2
0.0003
0.046
0.029
0.003
0.002
1.0**
0.46**
0.002**
0.008
0.03
0.03
0.003
0.03
0.033
0.81
0.002
0.008
0.002
0.004
0.03
0.002
0.029
0.03
MDMA 10-4M 
Mean ± SEM
7
4
4
7
6
4
4
5
5
4
4
6
4
7
4
6
5
6
5
4
6
4
5
169.5 ± 12.5
127.0 ± 5.3
Dopamine 10-4M
DRA/siRNA
Mean ± SEM
215.5 ± 49.8
208.5 ± 42.1
188.5 ± 42.7
67.9 ± 20.0
99.1 ± 19.8
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